Top Story

Insulin use, dialysis predicted poor wound healing after endovascular therapy

August 28, 2014

Patients undergoing endovascular therapy for critical limb ischemia were significantly more likely to have non-healing wounds if they used insulin, were dependent on hemodialysis or had major tissue loss, according to recent findings.

The researchers aimed to determine factors associated with non-healing of wounds in patients who have undergone successful endovascular therapy for critical limb ischemia (CLI). They suggested that comorbidities particular to the patient, vascular anatomy, wound features and interventional strategies may predict the probability of wound healing.

figure In the JournalsPerspective

DEFINITIVE LE published: Directional atherectomy effective regardless of diabetes status

August 27, 2014
Patients with or without diabetes who underwent directional atherectomy for peripheral artery disease experienced similar rates of primary patency at 12 months…

Nutrition education lacking in medical training

August 26, 2014
A group of physicians are questioning how well doctors can provide nutrition information and counseling to patients, particularly those with CVD, obesity and diabetes…

AHA and ADA: CV risk assessment, monitoring essential for patients with type 1 diabetes

August 21, 2014
A greater understanding of the pathophysiology, risk prediction and treatment of CVD in patients with type 1 diabetes is essential to minimize the impact of these…
CME

Individualizing T2DM Treatment: Determining Optimal Pathways that Lead to Achieving Target Goals

This activity is supported by educational grants from Lilly and Novo Nordisk.

10/11/2013
The prevalence of type 2 diabetes mellitus has escalated in recent years and targeting treatmentcontinues to be a…
More »
CME

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

12/30/2013
Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »

Filter By:

Meeting News Coverage

EXAMINE: Alogliptin showed no effect on CV mortality, HF hospitalization

March 30, 2014
WASHINGTON — Alogliptin, a dipeptidyl-peptidase IV inhibitor, was not associated with increased risk for CV mortality or hospitalization for…
Meeting News Coverage

EXAMINE: Alogliptin showed no effect on CV mortality, HF hospitalization

Cardiology Today, May 2014
WASHINGTON — Alogliptin, a dipeptidyl-peptidase IV inhibitor, was not associated with increased risk for CV mortality or hospitalization for…
In the Journals

Blood glucose measures offered little benefit for CVD risk prediction

March 25, 2014
Assessment of HbA1c values in the context of CVD risk assessment may provide little incremental benefit for the prediction of CVD risk in people…
In the Journals

Hyperglycemia at hospitalization increased risk for future diabetes in MI patients

March 14, 2014
Approximately one in six patients hospitalized for acute MI have hyperglycemia without known diabetes, and these patients are at a 2.5-fold increased…
In the Journals

Cardiac death, MI remain increased in patients with diabetes treated with DES

March 13, 2014
Among patients treated with drug-eluting stents during the DES era, researchers observed a higher rate of death or MI in those with diabetes compared…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

March 12, 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

Cardiology Today, April 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

March 7, 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

Cardiology Today, April 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
FDA approvals Perspective

FDA approves Myalept for treatment of lipodystrophy

February 25, 2014
The FDA today approved metreleptin, in combination with diet, for the treatment of complications of leptin deficiency in patients with congenital…
More Headlines »